Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep-wake disturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways passage (commonly of an animal) or illusions were present in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor hallucinations had a higher depression score than non-hallucinators but did not differ in other respects. Logistic regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when minor hallucinations are included, the total prevalence is much higher than previously reported. A simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances, and possibly other factors related to the duration of the disease, act as cofactors.

[1]  E. Mohr,et al.  Late cognitive changes in Parkinson's disease with an emphasis on dementia. , 1995, Advances in neurology.

[2]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[3]  P. Rondot,et al.  Mental disorders in Parkinson's disease after treatment with L-DOPA. , 1984, Advances in neurology.

[4]  F Lhermitte,et al.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? , 1989, Journal of neurology, neurosurgery, and psychiatry.

[5]  E Tulving,et al.  Priming and human memory systems. , 1990, Science.

[6]  T. Ala,et al.  Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[7]  A. Flahault,et al.  Neuropsychological prediction of dementia in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[8]  J. Wass,et al.  Psychotic reactions during treatment of pituitary tumours with dopamine agonists. , 1984, British medical journal.

[9]  J. Cummings.  Managing psychosis in patients with Parkinson's disease. , 1999, New England Journal of Medicine.

[10]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[11]  J. Fermanian,et al.  Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. , 1995, Behavioural neurology.

[12]  J. Cummings,et al.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. , 1999, Archives of neurology.

[13]  J. Cummings,et al.  Risk factors for depression in Parkinson disease. , 1997, Archives of neurology.

[14]  A. Korczyn,et al.  Auditory hallucinations in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[15]  F. Andermann,et al.  Complex visual hallucinations. Clinical and neurobiological insights. , 1998, Brain : a journal of neurology.

[16]  S. Leurgans,et al.  Poor visual discrimination and visual hallucinations in Parkinson's disease. , 1998, Clinical neuropharmacology.

[17]  H. Przuntek,et al.  Distorted color discrimination in ‘de nova’ parkinsonian patients , 1995, Neurology.

[18]  W. Dewi Rees.  The hallucinations of widowhood. , 1971, British medical journal.

[19]  A. Grimby.  Bereavement among elderly people: grief reactions, post‐bereavement hallucinations and quality of life , 1993, Acta psychiatrica Scandinavica.

[20]  I. Bodis-Wollner.  Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients , 1990, Trends in Neurosciences.

[21]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[22]  M. Esiri,et al.  Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[23]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[24]  S. Leurgans,et al.  Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[25]  R. Albin,et al.  Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[27]  W. Weiner,et al.  Complications of chronic levodopa therapy , 1981, Neurology.

[28]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[29]  J. Friedman,et al.  The management of the levodopa psychoses. , 1991, Clinical neuropharmacology.

[30]  R. H. Perry,et al.  Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness , 1995, Brain and Cognition.

[31]  R. Teunisse,et al.  Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome , 1996, The Lancet.

[32]  Z Walker,et al.  A preliminary investigation of laterality in Parkinson’s disease and susceptibility to psychosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[33]  G. Stebbins,et al.  Risk factors for nursing home placement in advanced Parkinson's disease , 1993, Neurology.

[34]  A L Benabid,et al.  Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. , 1998, Brain : a journal of neurology.

[35]  Ropinirole without levodopa in Parkinson's disease , 1990, The Lancet.

[36]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[37]  S. Factor,et al.  Parkinson's disease: drug-induced psychiatric states. , 1995, Advances in neurology.

[38]  R. Grünewald,et al.  Hallucinosis in idiopathic Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[39]  D. Jeste,et al.  Psychotic Symptoms in Parkinson's Disease Patients with Dementia , 1996, Journal of the American Geriatrics Society.

[40]  Diane Vizine-Goetz,et al.  Spectrum , 2001 .

[41]  E. Mori,et al.  Cognitive loss in dementia with Lewy bodies and Alzheimer disease. , 1998, Archives of neurology.

[42]  A. C. Roberts,et al.  Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction , 1989, Neuropsychologia.

[43]  G. Stebbins,et al.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease , 1995, Neurology.

[44]  H. Klawans,et al.  Levodopa-induced psychosis: a kindling phenomenon. , 1978, The American journal of psychiatry.

[45]  C. Tanner,et al.  Polysomnographic sleep measures in Parkinson's disease patients with treatment‐induced hallucinations , 1993, Annals of neurology.

[46]  N L Foster,et al.  Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference , 1997, Annals of neurology.

[47]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.